Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer

• Status: Not yet recruiting
• Trial end date: 2026-01-01

Summary

ISIdE is an European, multicentric study that aims to assess the efficacy of Sacituzumab Govitecan (SG) in locally advanced or metastatic triple-negative breast cancer where the disease has progressed despite chemotherapy or within 6 months after the end of curative treatments in order to:

1. evaluate the treatment efficacy in less pretreated patients.

2. identify biomarkers that could predict response or resistance to the drug.

100 patients will be included in this trial.

• Phase: Phase 3

Details

• Lead Sponsor: UNICANCER
• Collaborator: Gilead Sciences